2.73
price down icon6.83%   -0.20
after-market アフターアワーズ: 2.74 0.01 +0.37%
loading
前日終値:
$2.93
開ける:
$2.92
24時間の取引高:
324.04K
Relative Volume:
1.88
時価総額:
$71.65M
収益:
-
当期純損益:
$-94.11M
株価収益率:
-0.4542
EPS:
-6.01
ネットキャッシュフロー:
$-86.06M
1週間 パフォーマンス:
-20.41%
1か月 パフォーマンス:
-46.47%
6か月 パフォーマンス:
-66.95%
1年 パフォーマンス:
-75.93%
1日の値動き範囲:
Value
$2.715
$3.035
1週間の範囲:
Value
$2.715
$3.71
52週間の値動き範囲:
Value
$2.715
$11.87

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name
名前
Adverum Biotechnologies Inc
Name
セクター
Healthcare (1155)
Name
電話
(650) 649-1004
Name
住所
100 CARDINAL WAY, REDWOOD CITY, CA
Name
職員
155
Name
Twitter
@adverumbio
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
ADVM's Discussions on Twitter

ADVM を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ADVM
Adverum Biotechnologies Inc
2.73 71.65M 0 -94.11M -86.06M -6.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-06-25 開始されました Oppenheimer Outperform
2024-04-30 開始されました H.C. Wainwright Buy
2022-07-07 アップグレード Truist Hold → Buy
2021-07-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2021-05-03 ダウングレード SVB Leerink Outperform → Mkt Perform
2021-04-29 ダウングレード Chardan Capital Markets Buy → Neutral
2021-04-29 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-04-29 ダウングレード Truist Buy → Hold
2020-12-16 開始されました UBS Neutral
2020-11-12 アップグレード Raymond James Underperform → Mkt Perform
2020-06-26 ダウングレード Raymond James Mkt Perform → Underperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-05-05 アップグレード SunTrust Hold → Buy
2020-04-28 開始されました Goldman Buy
2020-03-16 開始されました SVB Leerink Outperform
2020-02-10 アップグレード Cantor Fitzgerald Neutral → Overweight
2020-02-10 アップグレード Chardan Capital Markets Neutral → Buy
2019-10-15 繰り返されました Chardan Capital Markets Neutral
2019-09-13 繰り返されました Chardan Capital Markets Neutral
2019-06-14 再開されました Raymond James Mkt Perform
2018-11-02 ダウングレード Raymond James Outperform → Mkt Perform
2018-11-02 ダウングレード SunTrust Buy → Hold
2018-09-21 開始されました Cantor Fitzgerald Overweight
2018-08-30 開始されました SunTrust Buy
2018-02-15 再開されました Piper Jaffray Overweight
2017-10-12 開始されました Raymond James Outperform
すべてを表示

Adverum Biotechnologies Inc (ADVM) 最新ニュース

pulisher
Apr 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com

Apr 21, 2025
pulisher
Apr 21, 2025

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com

Apr 20, 2025
pulisher
Apr 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com

Apr 18, 2025
pulisher
Apr 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com

Apr 17, 2025
pulisher
Apr 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.

Apr 17, 2025
pulisher
Apr 17, 2025

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Apr 17, 2025
pulisher
Apr 16, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com

Apr 16, 2025
pulisher
Apr 16, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 16, 2025
pulisher
Apr 16, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com

Apr 16, 2025
pulisher
Apr 15, 2025

Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Adverum Biotechnologies: Q4 Earnings Snapshot - CT Insider

Apr 15, 2025
pulisher
Apr 15, 2025

Adverum Biotechnologies, Inc. (ADVM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com

Apr 15, 2025
pulisher
Apr 15, 2025

ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire

Apr 15, 2025
pulisher
Apr 15, 2025

Adverum Biotechnologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Adverum Biotechnologies Reports Fourth Quarter and Full - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Adverum Advances Gene Therapy Pipeline Despite Wider Losses: Key Q4 Developments Revealed - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Adverum Biotechnologies, Inc. SEC 10-K Report - TradingView

Apr 15, 2025
pulisher
Apr 14, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire

Apr 14, 2025
pulisher
Apr 12, 2025

Avalanche Biotechnologies Announces Executive Changes - MarketScreener

Apr 12, 2025
pulisher
Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Apr 09, 2025
pulisher
Apr 04, 2025

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Apr 04, 2025
pulisher
Apr 04, 2025

Adverum Biotech Grants 30,000 Share Options to New Executive: Key Details - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

Adverum biotechnologies sees $147k stock purchase by major shareholder - Investing.com Australia

Apr 03, 2025
pulisher
Apr 02, 2025

Adverum Biotechnologies, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your RightsADVM - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Adverum Biotechnologies Inc expected to post a loss of $1.36 a shareEarnings Preview - TradingView

Apr 02, 2025
pulisher
Mar 31, 2025

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Exclusive: Adverum Gene Therapy Updates Coming at Major Ophthalmology Conference - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Adverum biotechnologies investor Leonard Braden Michael buys $188,930 in stock By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 20, 2025

Adverum biotechnologies sees insider purchase totaling $587,574 By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Adverum biotechnologies sees insider purchase totaling $587,574 - Investing.com

Mar 20, 2025
pulisher
Mar 10, 2025

Adverum Biotechnologies (ADVM) to Release Earnings on Monday - Defense World

Mar 10, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 03, 2025

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD - Marketscreener.com

Mar 03, 2025
pulisher
Mar 03, 2025

Adverum launches phase 3 trial for wet AMD gene therapy By Investing.com - Investing.com UK

Mar 03, 2025
pulisher
Mar 03, 2025

Can This One-Time Gene Therapy Revolutionize Wet AMD Treatment? Adverum's Phase 3 Trial Begins - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Adverum Biotechnologies initiates ARTEMIS study - TipRanks

Mar 03, 2025
pulisher
Mar 01, 2025

Adverum biotechnologies sees $1.44 million stock purchase by major shareholder - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

How Adverum is Attracting Talent: New Employees Receive $186,000 in Equity Grants - StockTitan

Feb 28, 2025

Adverum Biotechnologies Inc (ADVM) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
大文字化:     |  ボリューム (24 時間):